AZ | pharmaphorum

Friday 16 May 2025

Channels

Content type

Categories

Categories

Sort by

Order

AZ

News

astrazeneca-sign

AstraZeneca’s respiratory biologic fails again in COPD

AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

AstraZeneca spies an upturn at last in 2018

AstraZeneca (AZ) will see growth in its revenues once again in 2018, after several years of decline caused by blockbuster expiries.

Views & Analysis

AstraZeneca's new HQ in Cambridge is part of a huge expansion, which is testing the ancient city's infrastructure

AZ looks to pay-for-performance to bolster cardio-diabetes f...

While many of the hopes and disappointments for AZ’s business are around oncology, it still needs its cardiovascular and diabetes portfolio to perform.

News

Pascal Soriot Astra Zeneca

Soriot commits to AstraZeneca as shares slide

AstraZeneca (AZ) has tried to put a brave face on today’s news that its immunotherapy combination is unlikely to be a contender in lung cancer.

Views & Analysis

Top pharmaceutical companies 2017

The Berlin Declaration – driving early action in type 2 diab...

International initiative helps countries focus on best policies for overcoming diabetes.

Views & Analysis

OpdivoLarge

The biggest pharma stories of 2016 so far

The top 10 pharma milestones of the year to date.